Down 49.7% in 4 Weeks, Here's Why Coherus Oncology (CHRS) Looks Ripe for a Turnaround
Coherus Oncology Inc (CHRS) (Q3 2026) Earnings Call Highlights: Cost Cuts, Loqtorzi Growth and ...
Coherus Oncology, Inc. Q3 2026 Earnings Call Summary
Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $8
Coherus Oncology: 3 Key Takeaways for Long-Term Investors
Coherus Oncology (CHRS) Q3 2026 Earnings Call Transcript
What Coherus Oncology (CHRS) Said on Its Q3 Earnings Call
Coherus Oncology, Inc. (CHRS) Q3 2026 Earnings Call Transcript
Coherus Oncology: Q3 Earnings Snapshot
Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan
Coherus BioSciences Q3 2026 Earnings Call Transcript
Coherus Technologu Reduces Headcount By ~30%; Anticipates Core Cash Burn By $6M - $7M Quarterly Over Next Two Quarters
Coherus BioSciences Q3 Adj. EPS $(0.20) Beats $(0.22) Estimate, Sales $14.274M Miss $16.005M Estimate
Will Coherus Oncology (CHRS) Report Negative Earnings Next Week? What You Should Know
HC Wainwright & Co. Assumes Coherus Oncology at Buy, Announces Price Target of $7
Coherus Oncology, Inc. (CHRS) Discusses Tagmokitug Interim Clinical Data in Esophageal Cancer Transcript
Coherus Oncology Reports 89% Response Rate in Early ESCC Study
Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development
Coherus to Participate in Upcoming Investor Conferences
Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.